NewsEvents

Your Yourlocation: Home > Oxygen, oral theophylline release tablets, inhaled tiotropium bromide(136310-93-5) and other treatment

Study on the clinical efficacy and serum matrix metalloproteinase-9 (MMP-9) in patients with stable chronic obstructive pulmonary disease (COPD) complicated with respiratory failure. Long-term stable NIPPV in patients with severe COPD complicated with respiratory failure can significantly improve the quality of life and reduce serum MMP-9 levels. The article published on "International Journal of Respiratory Medicine".

80 patients with stable COPD complicated with respiratory failure were divided into experimental group and control group according to their tolerability and long-term NIPPV treatment. The patients in the two groups were given oxygen, oral theophylline, tiotropium bromide(136310-93-5) and other treatment, the experimental group on this basis, plus double-level NIPPV treatment for 1 year. (SGRQ), dyspnea score (MMRC score), 6-minute walking distance (6-MWD), arterial oxygen pressure (PaO2), arterial blood carbon dioxide partial pressure (PaCO2) before and after treatment in the two groups were observed. (FEV1% pred) and serum MMP-9 were recorded. The acute exacerbation and hospitalization were recorded at 1 year and 1 year after treatment.

Before and after treatment, the SGRQ score, MMRC score, 6-MWD, PaO2, PaCO2, FEV1% pred and serum MMP-9 in the experimental group were (63.60 ± 3.92) (51.93 ± 3.77), (3.65 ± 0.48) (66.58 ± 2.23) mm Hg, (60.58 ± 2.89) mm Hg (51.55 ± 2.28) mm, (56.88 ± 1.63) mm vs (248.00 ± 9.32) (P <0.05). The scores of SGRQ, MMRC, 6-MWD, PaO2, PaCO2, PaCO2, PaO2, PaCO2 were significantly higher in the control group than those in the control group before and after treatment(P <0.05), Hg, (38.68 ± 3.17) vs (42.05 ± 3.11), (182.85 ± 6.62) μg /L (170.93 ± 6.51) FEV1% pred and serum MMP-9 were (64.40 ± 4.33) (53.75 ± 3.73), (3.73 ± 0.45) (2.83 ± 0.39), (156.50 ± 5.88) m and (211.43 ± 7.53) (55.98 ± 3.36) mm Hg, (38.85 ± 2.77) vs (40.80 ± 3.16) mmHg, (59.60 ± 3.49) mm Hg, (172.83 ± 5.22) μg /L, the improvement of experimental group was better than that of the control group (P <0.05 or P <0.01), the number of acute attack and the number of days of hospitalization were significantly reduced.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved